{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:31:14Z","timestamp":1790775074624,"version":"4.1.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-002-205-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-002-205-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["\"Center of Excellence for Metabolic Associated Fatty Liver Disease"],"award-info":[{"award-number":["\"Center of Excellence for Metabolic Associated Fatty Liver Disease"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["National Sun Yat-sen University"],"award-info":[{"award-number":["National Sun Yat-sen University"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["Kaohsiung\" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project"],"award-info":[{"award-number":["Kaohsiung\" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12072-024-10699-x","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T06:03:09Z","timestamp":1723096989000},"page":"897-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD"],"prefix":"10.1007","volume":"18","author":[{"given":"Chun-Jen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-1900","authenticated-orcid":false,"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"10699_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u2013209","journal-title":"J Hepatol"},{"key":"10699_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/v12080815","volume":"12","author":"CJ Liu","year":"2020","unstructured":"Liu CJ, Chen PJ. Elimination of hepatitis B in highly endemic settings: lessons learned in Taiwan and challenges ahead. Viruses. 2020;12:815","journal-title":"Viruses"},{"key":"10699_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41575-018-0055-0","volume":"16","author":"MCS Wong","year":"2019","unstructured":"Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16:57\u201373","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10699_CR4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s12072-023-10568-z","volume":"17","author":"K Vaz","year":"2023","unstructured":"Vaz K, Clayton-Chubb D, Majeed A, Lubel J, Simmons D, Kemp W, et al. Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes. Hepatol Int. 2023;17:1082\u20131097","journal-title":"Hepatol Int"},{"key":"10699_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","volume":"67","author":"JG Fan","year":"2017","unstructured":"Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862\u2013873","journal-title":"J Hepatol"},{"key":"10699_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384","journal-title":"Hepatology"},{"key":"10699_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/kjm2.12345","volume":"37","author":"ML Yu","year":"2021","unstructured":"Yu ML, Chuang WL. Path from the discovery to the elimination of hepatitis C virus: honoring the winners of the nobel prize in physiology or medicine 2020. Kaohsiung J Med Sci. 2021;37:7\u201311","journal-title":"Kaohsiung J Med Sci"},{"key":"10699_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/apt.15131","volume":"49","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Henry L, Janus PO, Tanaka A, Eguchi Y, Mizokami M, et al. Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. Aliment Pharmacol Ther. 2019;49:644\u2013653","journal-title":"Aliment Pharmacol Ther"},{"key":"10699_CR9","unstructured":"World Health Organization. Global status report on alcohol and health 2018. https:\/\/www.who.int\/publications\/i\/item\/9789241565639 (2019). Accessed 1 Dec 2023."},{"issue":"10200","key":"10699_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0140-6736(19)31775-1","volume":"394","author":"AF Carvalho","year":"2019","unstructured":"Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet. 2019;394(10200):781\u2013792","journal-title":"Lancet"},{"key":"10699_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3748\/wjg.v25.i3.282","volume":"25","author":"WK Seto","year":"2019","unstructured":"Seto WK. Chronic hepatitis B and metabolic risk factors: a call for rigorous longitudinal studies. World J Gastroentrol. 2019;25:282\u2013286","journal-title":"World J Gastroentrol"},{"key":"10699_CR12","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jfma.2020.05.027","volume":"119","author":"HJ Su","year":"2020","unstructured":"Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, et al. Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. J Formos Med Assoc. 2020;119:1476\u20131482","journal-title":"J Formos Med Assoc"},{"key":"10699_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5009\/gnl20218","volume":"15","author":"SC Huang","year":"2021","unstructured":"Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, et al. Clinical and histologic features of patients with biopsy-proven metabolic dysfunction-associated fatty liver disease. Gut Liver. 2021;15:451\u2013458","journal-title":"Gut Liver"},{"key":"10699_CR14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.cgh.2019.06.036","volume":"18","author":"F \u00c5berg","year":"2020","unstructured":"\u00c5berg F, Puukka P, Salomaa V, M\u00e4nnist\u00f6 S, Lundqvist A, Valsta L, et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease. Clin Gastroenterol Hepatol. 2020;18:995\u2013997","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10699_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2011.09.013","volume":"56","author":"VS Wong","year":"2012","unstructured":"Wong VS, Wong GH, Chu WW, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533\u2013540","journal-title":"J Hepatol"},{"key":"10699_CR16","doi-asserted-by":"publisher","first-page":"454","DOI":"10.4103\/0377-4929.85074","volume":"54","author":"P Sakhuja","year":"2011","unstructured":"Sakhuja P, Kumar A, Hissar S, et al. Steatosis in chronic hepatitis B: prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol. 2011;54:454\u2013459","journal-title":"Indian J Pathol Microbiol"},{"key":"10699_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/apt.15575","volume":"51","author":"CC Wang","year":"2020","unstructured":"Wang CC, Cheng PN, Kao JH. Systemic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther. 2020;51:216\u2013230","journal-title":"Aliment Pharmacol Ther"},{"key":"10699_CR18","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/j.1440-1746.2011.06801.x","volume":"26","author":"MV Machado","year":"2011","unstructured":"Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26:1361\u20131367","journal-title":"J Gastroenterol Hepatol"},{"key":"10699_CR19","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/hep.28917","volume":"65","author":"EJ Joo","year":"2017","unstructured":"Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology. 2017;65:828\u2013835","journal-title":"Hepatology"},{"key":"10699_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/apt.12658","volume":"39","author":"GL Wong","year":"2014","unstructured":"Wong GL, Chan HL, Yu Z, Chan AW, Choi PC, Chim AM, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B\u2013a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther. 2014;39:883\u2013893","journal-title":"Aliment Pharmacol Ther"},{"key":"10699_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1053\/j.gastro.2017.07.001","volume":"153","author":"MW Yu","year":"2017","unstructured":"Yu MW, Lin CL, Liu CJ, Yang SH, Tseng YL, Wu CF. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study. Gastroenterology. 2017;153:1006\u20131017","journal-title":"Gastroenterology"},{"key":"10699_CR22","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1016\/j.cgh.2023.03.024","volume":"21","author":"LA Patmore","year":"2023","unstructured":"Patmore LA, Katwaroe WK, van der Spek D, et al. Association between the presence of metabolic comorbidities and liver-related events in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2023;21:3089\u20133096","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10699_CR23","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s12072-023-10545-6","volume":"17","author":"SC Huang","year":"2023","unstructured":"Huang SC, Su TH, Tseng TC, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int. 2023;17:1139\u20131149","journal-title":"Hepatol Int"},{"key":"10699_CR24","unstructured":"Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liu CH, et al. Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion. Clin Gastroenterol Hepatol. 2023:S1542\u20133565(23)00842-X."},{"key":"10699_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5152\/tjg.2015.150348","volume":"27","author":"B Ceylan","year":"2016","unstructured":"Ceylan B, Arslan F, Bat\u0131rel A, Fincanc\u0131 M, Yard\u0131mc\u0131 C, Fersan E, et al. Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir. Turk J Gastroenterol. 2016;27:42\u201346","journal-title":"Turk J Gastroenterol"},{"key":"10699_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3350\/cmh.2018.0104","volume":"25","author":"JH Yu","year":"2019","unstructured":"Yu JH, Lee JW. How does hepatic steatosis affect the outcome of patients with chronic hepatitis B? Clin Mol Hepatol. 2019;25:280\u2013282","journal-title":"Clin Mol Hepatol"},{"key":"10699_CR27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/apt.13804","volume":"44","author":"WK Seto","year":"2016","unstructured":"Seto WK, Fung J, Cheung KS, Mak LY, Hui RW, Liu KS, et al. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2016;44:1071\u20131079","journal-title":"Aliment Pharmacol Ther"},{"key":"10699_CR28","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/apt.16595","volume":"54","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Zou B, Wu Y, Yeo Y, Wu H, Stave CD, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther. 2021;54:1100\u20131109","journal-title":"Aliment Pharmacol Ther"},{"key":"10699_CR29","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12072-018-9877-7","volume":"12","author":"D Hu","year":"2018","unstructured":"Hu D, Wang H, Wang H, Wang Y, Wan X, Yan W, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int. 2018;12:438\u2013446","journal-title":"Hepatol Int"},{"key":"10699_CR30","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s11010-021-04143-z","volume":"477","author":"Q Liu","year":"2022","unstructured":"Liu Q, Mu M, Chen H, Zhang G, Yang Y, Chu Y, et al. Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress. Mol Cell Biochem. 2022;477:2481\u20132491","journal-title":"Mol Cell Biochem"},{"key":"10699_CR31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/apt.13770","volume":"44","author":"M Munteanu","year":"2016","unstructured":"Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, et al. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment Pharmacol Ther. 2016;44:877\u2013889","journal-title":"Aliment Pharmacol Ther"},{"key":"10699_CR32","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jhep.2017.01.003","volume":"66","author":"J Boursier","year":"2017","unstructured":"Boursier J, de Ledinghen V, Leroy V, Anty R, Francque S, Salmon D, et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol. 2017;66:1158\u20131165","journal-title":"J Hepatol"},{"key":"10699_CR33","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.dld.2017.03.013","volume":"49","author":"L Xu","year":"2017","unstructured":"Xu L, Lu W, Li P, Shen F, Mi YQ, Fan JG. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B. Dig Liver Dis. 2017;49:910\u2013917","journal-title":"Dig Liver Dis"},{"key":"10699_CR34","doi-asserted-by":"publisher","first-page":"8793278","DOI":"10.1155\/2017\/8793278","volume":"2017","author":"J Liang","year":"2017","unstructured":"Liang J, Liu F, Wang F, Han T, Jing L, Ma Z, et al. A noninvasive score model for prediction of NASH in patients with chronic hepatitis B and nonalcoholic fatty liver disease. BioMed Res Int. 2017;2017:8793278","journal-title":"BioMed Res Int"},{"key":"10699_CR35","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.3892\/mmr.2015.3299","volume":"11","author":"DR Dong","year":"2015","unstructured":"Dong DR, Hao MN, Li C, Peng Z, Liu X, Wang GP, et al. Acoustic radiation force impulse elastography, FibroScan\u00ae, Forns\u2019 index and their combination in the assessment of liver fibrosis in patients with chronic hepatitis B, and the impact of inflammatory activity and steatosis on these diagnostic methods. Mol Med Rep. 2015;11:4174\u20134182","journal-title":"Mol Med Rep"},{"key":"10699_CR36","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/cancers13071599","volume":"13","author":"Y Cho","year":"2021","unstructured":"Cho Y, Cho EJ, Yoo JJ, et al. Association between lipid profiles and the incidence of hepatocellular carcinoma: a nationwide population-based study. Cancers (Basel). 2021;13:1599","journal-title":"Cancers (Basel)"},{"key":"10699_CR37","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/jgh.13536","volume":"32","author":"AW Chan","year":"2017","unstructured":"Chan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 2017;32:667\u2013676","journal-title":"J Gastroenterol Hepatol"},{"key":"10699_CR38","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/jvh.13872","volume":"30","author":"R Zhou","year":"2023","unstructured":"Zhou R, Yang L, Zhang B, Gu Y, Kong T, Zhang W, et al. Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: a systematic review and meta-analysis. J Viral hepat. 2023;30:793\u2013802","journal-title":"J Viral hepat"},{"key":"10699_CR39","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3350\/cmh.2023.0004","volume":"29","author":"YJ Wong","year":"2023","unstructured":"Wong YJ, Nguyen VH, Yang HI, Li J, Le MH, Wu WJ, et al. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis. Clin Mol Hepatol. 2023;29:705\u2013720","journal-title":"Clin Mol Hepatol"},{"key":"10699_CR40","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/hep.32716","volume":"77","author":"LY Mak","year":"2023","unstructured":"Mak LY, Hui RW, Lee CH, et al. Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes. Hepatology. 2023;77:606\u2013618","journal-title":"Hepatology"},{"key":"10699_CR41","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/j.1572-0241.2007.01181.x","volume":"102","author":"JF Huang","year":"2007","unstructured":"Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102:1237\u20131243","journal-title":"Am J Gastroenterol"},{"key":"10699_CR42","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/kjm2.12275","volume":"36","author":"CF Huang","year":"2020","unstructured":"Huang CF, Dai CY, Yeh ML, Huang CI, Lee HC, Lai WT, et al. Cure or curd: modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication. Kaohsiung J Med Sci. 2020;36:920\u2013928","journal-title":"Kaohsiung J Med Sci"},{"key":"10699_CR43","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/apt.17233","volume":"56","author":"D Attia","year":"2022","unstructured":"Attia D, Abdel Alem S, El-Akel W, Abdel-Razek W, Eslam M, Fouad Y, et al. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study. Aliment Pharmacol Ther. 2022;56:1581\u20131590","journal-title":"Aliment Pharmacol Ther"},{"key":"10699_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jfma.2023.07.010","volume":"123","author":"KL Cheng","year":"2024","unstructured":"Cheng KL, Wang SW, Cheng YM, Hsieh TH, Wang CC, Kao JH. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease. J Formos Med Assoc. 2024;123:36\u201344","journal-title":"J Formos Med Assoc"},{"key":"10699_CR45","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1053\/j.gastro.2003.11.020","volume":"126","author":"A Lonardo","year":"2004","unstructured":"Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586\u2013597","journal-title":"Gastroenterology"},{"key":"10699_CR46","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jhep.2014.10.011","volume":"62","author":"CF Huang","year":"2015","unstructured":"Huang CF, Dai CY, Yeh ML, Huang CI, Tai CM, Hsieh MH, et al. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. J Hepatol. 2015;62:512\u2013518","journal-title":"J Hepatol"},{"key":"10699_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10699_CR48","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/01.mcg.0000135372.10846.2a","volume":"38","author":"ZM Younossi","year":"2004","unstructured":"Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. 2004;38:705\u2013709","journal-title":"J Clin Gastroenterol"},{"key":"10699_CR49","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00535-005-1586-z","volume":"40","author":"K Koike","year":"2005","unstructured":"Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol. 2005;40:329\u2013336","journal-title":"J Gastroenterol"},{"key":"10699_CR50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.trsl.2011.10.011","volume":"159","author":"MY Lu","year":"2012","unstructured":"Lu MY, Huang JF, Liao YC, Bai RK, Trieu RB, Chuang WL, et al. Mitochondrial polymorphism 12361A>G is associated with nonalcoholic fatty liver disease. Transl Res. 2012;159:58\u201359","journal-title":"Transl Res"},{"key":"10699_CR51","doi-asserted-by":"publisher","first-page":"22995","DOI":"10.1038\/srep22995","volume":"6","author":"MY Lu","year":"2016","unstructured":"Lu MY, Huang CI, Dai CY, Wang SC, Hsieh MY, Hsieh MH, et al. Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep. 2016;6:22995","journal-title":"Sci Rep"},{"key":"10699_CR52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3748\/wjg.v28.i1.140","volume":"28","author":"MY Lu","year":"2022","unstructured":"Lu MY, Yeh ML, Huang CI, Wang SC, Tsai YS, Tsai PC, et al. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. World J Gastroenterol. 2022;28:140\u2013153","journal-title":"World J Gastroenterol"},{"key":"10699_CR53","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jfma.2020.04.003","volume":"119","author":"ML Yu","year":"2020","unstructured":"Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, et al. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. J Formos Med Assoc. 2020;119:1019\u20131040","journal-title":"J Formos Med Assoc"},{"key":"10699_CR54","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/hep.31173","volume":"72","author":"JM Paik","year":"2020","unstructured":"Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72:1605\u20131616","journal-title":"Hepatology"},{"key":"10699_CR55","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10900-013-9792-8","volume":"39","author":"RJ Wong","year":"2014","unstructured":"Wong RJ, Chou C, Sinha SR, Kamal A, Ahmed A. Ethnic disparities in the association of body mass index with the risk of hypertension and diabetes. J Community Health. 2014;39:437\u2013445","journal-title":"J Community Health"},{"key":"10699_CR56","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.14218\/JCTH.2023.00399","volume":"11","author":"JF Huang","year":"2023","unstructured":"Huang JF, Tsai PC, Yeh ML, Huang CF, Huang CI, Lee MH, et al. Community-centered disease severity assessment of metabolic dysfunction-associated fatty liver disease. J Clin Transl Hepatol. 2023;11:1061\u20131068","journal-title":"J Clin Transl Hepatol"},{"key":"10699_CR57","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/gut.2009.192732","volume":"59","author":"F Negro","year":"2010","unstructured":"Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010;59:1279\u20131287","journal-title":"Gut"},{"key":"10699_CR58","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.29096","volume":"65","author":"C Oliveira","year":"2017","unstructured":"Oliveira C, Fournier C, Descamps V, Morel V, Scipione CA, Romagnuolo R, et al. Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles. Hepatology. 2017;65:1851\u20131864","journal-title":"Hepatology"},{"key":"10699_CR59","doi-asserted-by":"publisher","first-page":"12766","DOI":"10.1073\/pnas.96.22.12766","volume":"96","author":"V Agnello","year":"1999","unstructured":"Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA. 1999;96:12766\u201312771","journal-title":"Proc Natl Acad Sci USA"},{"key":"10699_CR60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2893.2005.00669.x","volume":"13","author":"A Lonardo","year":"2006","unstructured":"Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat. 2006;13:73\u201380","journal-title":"J Viral Hepat"},{"key":"10699_CR61","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0168-8278(00)00036-2","volume":"34","author":"L Serfaty","year":"2001","unstructured":"Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol. 2001;34:428\u2013434","journal-title":"J Hepatol"},{"key":"10699_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10576-z","author":"CI Shih","year":"2023","unstructured":"Shih CI, Wu KT, Hsieh MH, Yang JF, Chen YY, Tsai WL, et al. Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study. Hepatol Int. 2023. https:\/\/doi.org\/10.1007\/s12072-023-10576-z","journal-title":"Hepatol Int"},{"key":"10699_CR63","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3350\/cmh.2023.0359","volume":"29","author":"ML Yeh","year":"2023","unstructured":"Yeh ML, Yu ML. From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: updates of nomenclature and impact on clinical trials. Clin Mol Hepatol. 2023;29:969\u2013972","journal-title":"Clin Mol Hepatol"},{"key":"10699_CR64","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jhep.2008.12.017","volume":"50","author":"CY Dai","year":"2009","unstructured":"Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, et al. Insulin resistance predicts response to peginterferon-alpha\/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009;50:712\u2013718","journal-title":"J Hepatol"},{"key":"10699_CR65","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s12072-012-9388-x","volume":"7","author":"CH Chen","year":"2013","unstructured":"Chen CH, Huang JF, Huang CF, Yeh ML, Yang JF, Hsieh MY, et al. Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. Hepatol Int. 2013;7:162\u2013170","journal-title":"Hepatol Int"},{"key":"10699_CR66","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2012.01.051","volume":"221","author":"LE Adinolfi","year":"2012","unstructured":"Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis. 2012;221:496\u2013502","journal-title":"Atherosclerosis"},{"key":"10699_CR67","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jceh.2018.06.009","volume":"9","author":"G Rout","year":"2019","unstructured":"Rout G, Nayak B, Patel AH, Gunjan D, Singh V, Kedia S, et al. Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography. J Clin Exp Hepatol. 2019;9:207\u2013214","journal-title":"J Clin Exp Hepatol"},{"key":"10699_CR68","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3390\/diagnostics12030702","volume":"12","author":"A Trifan","year":"2022","unstructured":"Trifan A, Stratina E, Rotaru A, Stafie R, Zenovia S, Nastasa R, et al. Changes in liver steatosis using controlled attenuation parameter among patients with chronic hepatitis c infection treated with direct-acting antivirals therapy who achieved sustained virological response. Diagnostics (Basel). 2022;12:702","journal-title":"Diagnostics (Basel)"},{"key":"10699_CR69","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/hepr.13899","volume":"53","author":"Y Tokuchi","year":"2023","unstructured":"Tokuchi Y, Suda G, Kawagishi N, Ohara M, Kohya R, Sasaki T, et al. Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight. Hepatol Res. 2023;53:595\u2013606","journal-title":"Hepatol Res"},{"key":"10699_CR70","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.dld.2020.11.001","volume":"53","author":"A Cespiati","year":"2021","unstructured":"Cespiati A, Petta S, Lombardi R, Di Marco V, Calvaruso V, Bertelli C, et al. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): evaluation by the controlled attenuation parameter (CAP). Dig Liver Dis. 2021;53:1301\u20131307","journal-title":"Dig Liver Dis"},{"key":"10699_CR71","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.kjms.2017.07.003","volume":"33","author":"JF Huang","year":"2017","unstructured":"Huang JF, Huang CF, Yeh ML, Dai CY, Hsieh MH, Yang JF, et al. The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. Kaohsiung J Med Sci. 2017;33:567\u2013571","journal-title":"Kaohsiung J Med Sci"},{"key":"10699_CR72","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/jgh.14067","volume":"33","author":"LE Adinolfi","year":"2018","unstructured":"Adinolfi LE, Nevola R, Guerrera B, D\u2019Alterio G, Marrone A, Giordano M, et al. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33:1379\u20131382","journal-title":"J Gastroenterol Hepatol"},{"key":"10699_CR73","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/gut.2010.236158","volume":"61","author":"AJ Thompson","year":"2012","unstructured":"Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2\/3. Gut. 2012;61:128\u2013134","journal-title":"Gut"},{"key":"10699_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209615","volume":"13","author":"N Kawagishi","year":"2018","unstructured":"Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, et al. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS ONE. 2018;13: e0209615","journal-title":"PLoS ONE"},{"key":"10699_CR75","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/liv.13633","volume":"38","author":"YH Yen","year":"2018","unstructured":"Yen YH, Lin MT, Kuo FY, Chang KC, Tsai MC, Tseng PL, et al. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. Liver Int. 2018;38:1064\u20131073","journal-title":"Liver Int"},{"key":"10699_CR76","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13993","author":"T Sano","year":"2023","unstructured":"Sano T, Amano K, Ide T, Isoda H, Honma Y, Morita Y, et al. Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: a multicenter study. Hepatol Res. 2023. https:\/\/doi.org\/10.1111\/hepr.13993","journal-title":"Hepatol Res"},{"key":"10699_CR77","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/liv.15577","volume":"43","author":"S Pelusi","year":"2023","unstructured":"Pelusi S, Bianco C, Colombo M, Cologni G, Del Poggio P, Pugliese N, et al. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals. Liver Int. 2023;43:1593\u20131603","journal-title":"Liver Int"},{"key":"10699_CR78","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/hep.31500","volume":"72","author":"E Degasperi","year":"2020","unstructured":"Degasperi E, Galmozzi S, Pelusi R, D\u2019Ambrosio R, Soffredini, Borghi M, et al. Hepatic fat-genetic risk score predicts hepatocellular carcinoma in patients with cirrhotic HCV treated with DAAs. Hepatology. 2020;72:1912\u20131923","journal-title":"Hepatology"},{"key":"10699_CR79","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/apt.16346","volume":"53","author":"Y Fouad","year":"2021","unstructured":"Fouad Y, Lazarus JV, Negro F, Peck-Radosavljevic M, Sarin SK, Ferenci P, et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Aliment Pharmacol Ther. 2021;53:1080\u20131089","journal-title":"Aliment Pharmacol Ther"},{"issue":"17","key":"10699_CR80","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.2169\/internalmedicine.54.2736","volume":"54","author":"M Hirakawa","year":"2015","unstructured":"Hirakawa M, Arase Y, Amakawa K, Ohmoto-Sekine Y, Ishihara M, Shiba M, et al. Relationship between alcohol intake and risk factors for metabolic syndrome in men. Intern Med. 2015;54(17):2139\u20132145","journal-title":"Intern Med"},{"key":"10699_CR81","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.12659\/MSM.901309","volume":"23","author":"SK Kim","year":"2017","unstructured":"Kim SK, Hong SH, Chung JH, Cho KB. Association between alcohol consumption and metabolic syndrome in a community-based cohort of Korean adults. Med Sci Monit. 2017;23:2104\u20132110","journal-title":"Med Sci Monit"},{"key":"10699_CR82","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","volume":"78","author":"F \u00c5berg","year":"2023","unstructured":"\u00c5berg F, Byrne CD, Pirola CJ, M\u00e4nnist\u00f6 V, Sookoian S. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease. J Hepatol. 2023;78:191\u2013206","journal-title":"J Hepatol"},{"key":"10699_CR83","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/gutjnl-2013-305718","volume":"63","author":"S Sookoian","year":"2014","unstructured":"Sookoian S, Casta\u00f1o GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut. 2014;63:530\u2013532","journal-title":"Gut"},{"key":"10699_CR84","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3350\/cmh.2020.0163","volume":"26","author":"JH Choi","year":"2020","unstructured":"Choi JH, Sohn W, Cho YK. The effect of moderate alcohol drinking in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020;26:662\u2013669","journal-title":"Clin Mol Hepatol"},{"key":"10699_CR85","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41395-018-0133-5","volume":"113","author":"T Mitchell","year":"2018","unstructured":"Mitchell T, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Ching H, et al. Type and pattern of alcohol consumption is associated with liver fibrosis in patients with non-alcoholic fatty liver disease. Am J Gastroenterol. 2018;113:1484\u20131493","journal-title":"Am J Gastroenterol"},{"key":"10699_CR86","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/hep.30864","volume":"71","author":"F \u00c5berg","year":"2020","unstructured":"\u00c5berg F, Puukka P, Salomaa V, M\u00e4nnist\u00f6 S, Lundqvist A, Valsta L, et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts. Hepatology. 2020;71:835\u2013848","journal-title":"Hepatology"},{"key":"10699_CR87","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(22)00847-9","volume":"400","author":"GBD 2020 Alcohol Collaborators","year":"2022","unstructured":"GBD 2020 Alcohol Collaborators. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global burden of disease study 2020. Lancet. 2022;400:185\u2013235","journal-title":"Lancet"},{"key":"10699_CR88","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/hep.30170","volume":"69","author":"Y Chang","year":"2019","unstructured":"Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung HS, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology. 2019;69:64\u201375","journal-title":"Hepatology"},{"key":"10699_CR89","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41575-023-00822-y","volume":"20","author":"LA D\u00edaz","year":"2023","unstructured":"D\u00edaz LA, Arab JP, Louvet A, Bataller R, Arrese M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023;20:764\u2013783","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10699_CR90","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","volume":"31","author":"S Romeo","year":"2020","unstructured":"Romeo S, Sanyal A, Valenti L. Leveraging human genetics to identify potential new treatments for fatty liver disease. Cell Metab. 2020;31:35\u201345","journal-title":"Cell Metab"},{"key":"10699_CR91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/ng.488","volume":"42","author":"C Tian","year":"2010","unstructured":"Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010;42:21\u201323","journal-title":"Nat Genet"},{"key":"10699_CR92","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cmet.2019.08.018","volume":"30","author":"J Yuan","year":"2019","unstructured":"Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 2019;30:675-688.e7","journal-title":"Cell Metab"},{"key":"10699_CR93","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1038\/s41467-023-39028-w","volume":"14","author":"L Gan","year":"2023","unstructured":"Gan L, Feng Y, Du B, Fu H, Tian Z, Xue G, et al. Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae. Nat Commun. 2023;14:3215","journal-title":"Nat Commun"},{"key":"10699_CR94","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.33182","volume":"6","author":"JA Hahn","year":"2023","unstructured":"Hahn JA, Fatch R, Barnett NP, Marcus GM. Phosphatidylethanol vs transdermal alcohol monitoring for detecting alcohol consumption among adults. JAMA Netw Open. 2023;6: e2333182","journal-title":"JAMA Netw Open"},{"key":"10699_CR95","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jhep.2022.02.021","volume":"77","author":"F \u00c5berg","year":"2022","unstructured":"\u00c5berg F, Luukkonen PK, But A, Salomaa V, Britton A, Petersen KM, et al. Development and validation of a model to predict incident chronic liver disease in the general population: the CLivD score. J Hepatol. 2022;77:302\u2013311","journal-title":"J Hepatol"},{"key":"10699_CR96","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889\u2013919","journal-title":"Hepatol Int"},{"key":"10699_CR97","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u20131835","journal-title":"Hepatology"},{"key":"10699_CR98","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","volume":"74","author":"Z Boyer-Diaz","year":"2021","unstructured":"Boyer-Diaz Z, Aristu-Zabalza P, Andr\u00e9s-Rozas M, Robert C, Ortega-Ribera M, Fern\u00e1ndez-Iglesias A, et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J Hepatol. 2021;74:1188\u20131199","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10699-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10699-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10699-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T12:12:49Z","timestamp":1732623169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10699-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":98,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10699"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10699-x","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Chun-Jen Liu, Wai Kay Seto, Ming-Lung Yu, have not disclosed any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Writing assistance"}}]}}